Cochrane for Clinicians
Putting Evidence into Practice
Laxatives for the Management of Childhood Constipation
Am Fam Physician. 2017 Oct 1;96(7):433-434.
Author disclosure: No relevant financial affiliations.
Are laxatives an effective and safe treatment for functional childhood constipation?
Polyethylene glycol (PEG) is superior to placebo (mean difference [MD] = 2.61 more stools per week; 95% confidence interval [CI], 1.15 to 4.08), lactulose (MD = 0.70; 95% CI, 0.10 to 1.31), and milk of magnesia (MD = 0.69; 95% CI, 0.48 to 0.89) at increasing the number of bowel movements per week at two to 12 weeks. High-dose PEG (0.7 g per kg) is superior to low-dose PEG (0.3 g per kg) at increasing the number of stools per week (MD = 1.30; 95% CI, 0.76 to 1.84). PEG is not superior to enemas, flixweed, or liquid paraffin. There are no serious adverse effects associated with regular use of PEG. Common adverse effects with use of any of the tested laxatives include flatulence, abdominal pain, nausea, diarrhea, and headache.1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
Childhood constipation is a common disorder affecting up to 30% of children worldwide.2 It not only stresses the patient and family, but it is also a strain on the health care system. Children diagnosed with constipation visit the emergency department far more often than those without constipation3 and account for 3% of all general pediatric visits and 30% of all pediatric gastroenterology visits.1 Constipation in children costs the health care system $3.9 billion per year.2 Despite the widespread use of laxative medications in children, there is a relative lack of data on their effectiveness and safety.
This review included 25 randomized controlled trials with 2,310 participants who had functional constipation. Of all the treatments, PEG was studied the most extensively. After two weeks of treatment, patients treated with PEG (dosed based on age and clinical response, in one study 0.2 to 0.8 g per kg per day) had an increased number of bowel movements per week vs. patients who received placebo (two studies, 101 patients; MD = 2.61 more stools per week; 95% CI, 1.15 to 4.08). Patients treated with PEG demonstrated an increased number of stools compared with those treated with lactulose when comparisons were done at two to 12 weeks (six studies, 465 patients; MD = 0.70 more stools per week; 95% CI, 0.10 to 1.31). PEG treatment also resulted in increased bowel movements per week when compared with milk of magnesia after four weeks of treatment (three studies, 211 patients; MD = 0.69 more stools per week; 95% CI, 0.48 to 0.89).
In one study of 90 patients, treatment with high-dose PEG (0.7 g per kg) resulted in an increased number of bowel movements (MD = 1.30 stools per week; 95% CI, 0.76 to 1.84) vs. low-dose PEG (0.3 g per kg). No serious adverse effects were reported with PEG therapy at any dosing regimen.
Other treatment comparisons also looked at the outcome of number of stools per week. In one study of 50 patients, milk of magnesia (1 mL per kg per day) was superior to lactulose (1 to 3 mL per kg per day; MD = 1.51; 95% CI, 0.39 to 2.63), and two studies with a total of 287 patients showed that liquid paraffin (1 to 2 mL per kg twice daily) was superior to lactulose (1 to 2 mL per kg twice daily; MD = 4.94; 95% CI, 4.28 to 5.61). There was no statistically significant increase in the number of bowel movements per week among the following comparisons: PEG (loading dose = 1.5 g per kg for six days, then 0.5 g per kg daily) vs. enema (60 mL for children younger than six years or 120 mL for children older than six years, once daily); dietary fiber vs. lactulose (10 g of each in a 125-mL yogurt drink); senna (10 to 20 mL per day) vs. lactulose (10 to 15 mL per day); lactitol (250 to 400 mg per kg daily) vs. lactulose (500 to 750 mg per kg daily); hydrolyzed guar gum (3 to 5 g daily, depending on age) vs. lactulose (1 mL per kg daily); PEG (0.4 g per kg daily) vs. flixweed (2 to 3 g daily); PEG (0.5 to 1 g per kg daily) vs. dietary fiber (16.8 to 22.4 g daily); or PEG (20 mL per kg per hour for four hours or 1 to 1.5 g per kg daily) vs. liquid paraffin (30 mL per 10 kg twice daily for two days or 1 to 1.5 mL per kg daily).
Clinical guidelines from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition recommend PEG as the first-line treatment for children with fecal impaction and for maintenance therapy of functional constipation. Lactulose can be used as first-line maintenance therapy if PEG is not available. Milk of magnesia, mineral oil, and stimulant laxatives should be considered as second-line or additional therapy.4
The practice recommendations in this activity are available at http://www.cochrane.org/CD009118.
The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army, the U.S. Air Force, or the Department of Defense.
REFERENCESshow all references
1. Gordon M, MacDonald JK, Parker CE, Akobeng AK, Thomas AG. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev. 2016;(8):CD009118....
2. Liem O, Harman J, Benninga M, Kelleher K, Mousa H, Di Lorenzo C. Health utilization and cost impact of childhood constipation in the United States. J Pediatr. 2009;154(2):258–262.
3. Choung RS, Shah ND, Chitkara D, et al. Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. J Pediatr Gastroenterol Nutr. 2011;52(1):47–54.
4. Tabbers MM, DiLorenzo C, Berger MY, et al.; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258–274.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Nov 1, 2020
Access the latest issue of American Family Physician